Is DFS an Appropriate Surrogate for OS in Early HER2+ Breast Cancer?

Leggi l'articolo originale


The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.

Lascia un commento